These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30840447)

  • 1. Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
    Toledo-Sherman L; Breccia P; Cachope R; Bate JR; Angulo-Herrera I; Wishart G; Matthews KL; Martin SL; Cox HC; McAllister G; Penrose SD; Vater H; Esmieu W; Van de Poël A; Van de Bospoort R; Strijbosch A; Lamers M; Leonard P; Jarvis RE; Blackaby W; Barnes K; Eznarriaga M; Dowler S; Smith GD; Fischer DF; Lazari O; Yates D; Rose M; Jang SW; Muñoz-Sanjuan I; Dominguez C
    J Med Chem; 2019 Mar; 62(6):2988-3008. PubMed ID: 30840447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.
    Lu XH; Mattis VB; Wang N; Al-Ramahi I; van den Berg N; Fratantoni SA; Waldvogel H; Greiner E; Osmand A; Elzein K; Xiao J; Dijkstra S; de Pril R; Vinters HV; Faull R; Signer E; Kwak S; Marugan JJ; Botas J; Fischer DF; Svendsen CN; Munoz-Sanjuan I; Yang XW
    Sci Transl Med; 2014 Dec; 6(268):268ra178. PubMed ID: 25540325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.
    Tidball AM; Bryan MR; Uhouse MA; Kumar KK; Aboud AA; Feist JE; Ess KC; Neely MD; Aschner M; Bowman AB
    Hum Mol Genet; 2015 Apr; 24(7):1929-44. PubMed ID: 25489053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
    Van de Poël A; Toledo-Sherman L; Breccia P; Cachope R; Bate JR; Angulo-Herrera I; Wishart G; Matthews KL; Martin SL; Peacock M; Barnard A; Cox HC; Jones G; McAllister G; Vater H; Esmieu W; Clissold C; Lamers M; Leonard P; Jarvis RE; Blackaby W; Eznarriaga M; Lazari O; Yates D; Rose M; Jang SW; Muñoz-Sanjuan I; Dominguez C
    J Med Chem; 2021 Apr; 64(8):5018-5036. PubMed ID: 33783225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain Tumors.
    Rathi S; Oh JH; Zhang W; Mladek AC; Garcia DA; Xue Z; Burgenske DM; Zhang W; Le J; Zhong W; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2024 Jul; 390(2):260-275. PubMed ID: 38858089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined ataxia telangiectasia mutated and DNA-dependent protein kinase inhibition radiosensitizes Madin-Darby canine kidney cells.
    Koike M; Yutoku Y; Koike A
    J Vet Med Sci; 2022 Nov; 84(11):1485-1490. PubMed ID: 36104184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.
    Ladduwahetty T; Lee MR; Maillard MC; Cachope R; Todd D; Barnes M; Beaumont V; Chauhan A; Gallati C; Haughan AF; Kempf G; Luckhurst CA; Matthews K; McAllister G; Mitchell P; Patel H; Rose M; Saville-Stones E; Steinbacher S; Stott AJ; Thatcher E; Tierney J; Urbonas L; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2022 Jul; 65(14):9819-9845. PubMed ID: 35816678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ginsenoside compound K reduces the progression of Huntington's disease via the inhibition of oxidative stress and overactivation of the ATM/AMPK pathway.
    Hua KF; Chao AC; Lin TY; Chen WT; Lee YC; Hsu WH; Lee SL; Wang HM; Yang DI; Ju TC
    J Ginseng Res; 2022 Jul; 46(4):572-584. PubMed ID: 35818427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.
    Beconi M; Aziz O; Matthews K; Moumné L; O'Connell C; Yates D; Clifton S; Pett H; Vann J; Crowley L; Haughan AF; Smith DL; Woodman B; Bates GP; Brookfield F; Bürli RW; McAllister G; Dominguez C; Munoz-Sanjuan I; Beaumont V
    PLoS One; 2012; 7(9):e44498. PubMed ID: 22973455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.
    Wityak J; McGee KF; Conlon MP; Song RH; Duffy BC; Clayton B; Lynch M; Wang G; Freeman E; Haber J; Kitchen DB; Manning DD; Ismail J; Khmelnitsky Y; Michels P; Webster J; Irigoyen M; Luche M; Hultman M; Bai M; Kuok ID; Newell R; Lamers M; Leonard P; Yates D; Matthews K; Ongeri L; Clifton S; Mead T; Deupree S; Wheelan P; Lyons K; Wilson C; Kiselyov A; Toledo-Sherman L; Beconi M; Muñoz-Sanjuan I; Bard J; Dominguez C
    J Med Chem; 2015 Apr; 58(7):2967-87. PubMed ID: 25760409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a γH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D.
    Chwastek J; Jantas D; Lasoń W
    Int J Biochem Cell Biol; 2017 Jun; 87():38-53. PubMed ID: 28341201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
    Degorce SL; Barlaam B; Cadogan E; Dishington A; Ducray R; Glossop SC; Hassall LA; Lach F; Lau A; McGuire TM; Nowak T; Ouvry G; Pike KG; Thomason AG
    J Med Chem; 2016 Jul; 59(13):6281-92. PubMed ID: 27259031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
    Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
    Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
    Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L
    J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
    Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
    J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex.
    Maiuri T; Mocle AJ; Hung CL; Xia J; van Roon-Mom WM; Truant R
    Hum Mol Genet; 2017 Jan; 26(2):395-406. PubMed ID: 28017939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
    Pike KG; Barlaam B; Cadogan E; Campbell A; Chen Y; Colclough N; Davies NL; de-Almeida C; Degorce SL; Didelot M; Dishington A; Ducray R; Durant ST; Hassall LA; Holmes J; Hughes GD; MacFaul PA; Mulholland KR; McGuire TM; Ouvry G; Pass M; Robb G; Stratton N; Wang Z; Wilson J; Zhai B; Zhao K; Al-Huniti N
    J Med Chem; 2018 May; 61(9):3823-3841. PubMed ID: 29683659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.